Betaglue technologies: closing of a eur 10 million financing round

• Fin Posillipo (Petrone Group], Kairos Partners SGR, LIFTT, Neva Sgr (Intesa Sanpaoh Group), Profequycapital and Romedjoined the share capital Innogest Capital and Panakes Partners reinvest
• The financing will give BetaGlue Technologies the ability to further develop its advanced radiotherapy platform, BAT-90, and accelerate access to the Safe-Biopsy Device market, thus opening a new chapter in the fight against cancer

Milan, July 19,2022 - BetaGlue Technologies, a highly innovative company working in the Life Sciences sector, today announced the closing of a EUR 10 million equity financing round. Fin Posillipo (Petrone Group), Kairos Partners SGR LIFTT (Venture Capital led by Stefano Buono, founder of AAA), Neva Sgr (Intesa Sanpaolo Group), Profequycapital and Romed will be joining the company`s capital, with a reinvestment from existing investors Innogest Capital and Panakes Partners.

The investment will finance BetaGlue Technologies` future operations aimed at reaching a number of milestones in Europe and the US both for the development and approval of BAT-90, the company`s advanced radiotherapy platform. Key priorities in this development will be the completion of the clinical trials that are already underway in liver and breast cancer and their regulatory approval, as well as the completion of the industrial scale-up in Europe and the US of the safe-biopsy device, which has already been clinically tested in lung and liver biopsy.

BAT-90

BetaGlue has developed and patented BAT-90 ("Beta Ablation Therapy with Yttrium-90"), consisting of a p radiation-emitting biocompatible matrix, delivered to patients via percutaneous injection or during surgery: the Yttrium-90-labelled microspheres present inside the matrix are injected into the tumour and, as the carrier need few seconds to reach full polymerisation, they are retained exclusively in the injected area. This prevents the microspheres from spreading to surrounding tissues or organs, so as to release their radiation energy only to the target tumour. BAT-90 was developed at the Istituto Nazionale Tumori `Fondazione Pascale` in Naples, Italy, whereby the arterial infusion of 90Y-coated microspheres is performed into liver tumours (the so-called TARE) has been extended beyond this indication and route of delivery. This was achieved through the use of a fast-curing, biocompatible glue that effectively captures the radioactive microspheres, allowing them to be injected directly and safely into various target tissues. The latter can be either surgically unresectable tumours or metastases, which are thus irradiated in-loco, or surgical resection margins, which may still have residual cancer cells (the main cause of local recurrence), and which can be cleared with BAT-90.

Benefits

BAT-90 is a therapeutic nuclear medicine solution that is extremely precise (it only targets the tumour area), personalised (calibrated to the patient`s clinical situation), rapid (a single injection reaching full polymerisation in just a few minutes) and safe (the radiation energy is released where needed, avoiding exposure of surrounding tissues and organs, thus minimizing any risk to either patients or healthcare professionals). It opens up important horizons in oncology, benefitting both patients and the whole healthcare system.